{"id":453496,"date":"2021-03-09T07:33:14","date_gmt":"2021-03-09T12:33:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453496"},"modified":"2021-03-09T07:33:14","modified_gmt":"2021-03-09T12:33:14","slug":"harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/","title":{"rendered":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., March  09, 2021  (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33<sup>rd<\/sup> Annual Roth Conference. The panel discussion, titled \u201cPushing the Envelope on Bispecific Antibodies,\u201d will take place on Tuesday, March 16, 2021 at 3 p.m. ET (12 p.m. PT).<\/p>\n<p>A live audio webcast of the panel will be available in the Investors section of Harpoon Therapeutics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wGTKResV4izxZp0p7uLYeP-jdFdviHWZgopWy_FKSlPPTOARwR7N8_Yhe5gWDhqOHq3rtZu1C_nyfOTjuGPsNw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.harpoontx.com<\/a> with an archived replay available following the event.<\/p>\n<p>\n        <strong>About Harpoon Therapeutics<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body\u2019s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient\u2019s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC<sup>\u00ae<\/sup>) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1\/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1\/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1\/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1\/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC\u2122\u00a0platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wGTKResV4izxZp0p7uLYeJ9ZbnETn_7gN8lKyAcTCDQjnqHH_cJlzKNhP6LhROIbRCl6IPsp3WiClHRONH92dg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.harpoontx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Harpoon Therapeutics, Inc.<br \/>Georgia Erbez<br \/>Chief Financial Officer<br \/>650-443-7400<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O0DbGP8qTuM_pjGRLxEz-qTQdUDiIN6ZldVfghxIV0yGwm6PzRTFeyE3v5ASUsy9J9gDXthbpTzfGfUoOSJFJMKQs0BI-zHtma_rFZanKBE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@harpoontx.com<\/a><\/p>\n<p>Westwicke ICR<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858-356-5932 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qxNHmZUZqeN7IraAMr7P8S4u-luZWRfftkRQoaEB-8vRCKEctVnn9fnaju_yM8COWUe2we_tAf0AS0SwqdA64VI-FFANM4k0sMLCOSPOvjY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/65e81912-b5f1-4e45-b210-497e0dfbae22\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33rd Annual Roth Conference. The panel discussion, titled \u201cPushing the Envelope on Bispecific Antibodies,\u201d will take place on Tuesday, March 16, 2021 at 3 p.m. ET (12 p.m. PT). A live audio webcast of the panel will be available in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com with an archived replay available following the event. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Harpoon Therapeutics to Participate in 33rd Annual Roth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453496","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33rd Annual Roth Conference. The panel discussion, titled \u201cPushing the Envelope on Bispecific Antibodies,\u201d will take place on Tuesday, March 16, 2021 at 3 p.m. ET (12 p.m. PT). A live audio webcast of the panel will be available in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com with an archived replay available following the event. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell &hellip; Continue reading &quot;Harpoon Therapeutics to Participate in 33rd Annual Roth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T12:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference\",\"datePublished\":\"2021-03-09T12:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/\"},\"wordCount\":342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/\",\"name\":\"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\",\"datePublished\":\"2021-03-09T12:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33rd Annual Roth Conference. The panel discussion, titled \u201cPushing the Envelope on Bispecific Antibodies,\u201d will take place on Tuesday, March 16, 2021 at 3 p.m. ET (12 p.m. PT). A live audio webcast of the panel will be available in the Investors section of Harpoon Therapeutics\u2019 website at www.harpoontx.com with an archived replay available following the event. About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell &hellip; Continue reading \"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T12:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference","datePublished":"2021-03-09T12:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/"},"wordCount":342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/","name":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=","datePublished":"2021-03-09T12:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjU3MSM0MDU0NTI2IzIxMjU4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-to-participate-in-33rd-annual-roth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harpoon Therapeutics to Participate in 33rd Annual Roth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453496"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}